25 Apr, 2024 Amending ANDA by Purportedly Carving Out Infringing Use—After Trial—Does Not Rescue the Amended ANDA from the Negative PIV Judgment By Dan Liu The district court in Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc., Civil Action No. 20-430-RGA (D. Del.) was asked...
04 Dec, 2023 The Perils of Incorporation by Reference at the Federal Circuit By Ryan Hagglund Because judicial resources are limited, virtually all courts impose length limitations, such as word, page, or line limits, for briefing....
20 Nov, 2023 Investors File Class Action Suits against Insecticide Manufacturer Regarding Statements Concerning Patent Litigation By Ryan Hagglund Manufacturers of pharmaceuticals, biologics, and herbicides, as well as companies in virtually every industry, routinely make statements...
13 Nov, 2023 Federal Circuit Requires Analysis of Extrinsic Evidence in Construction of "a pH of 13" By Ryan Hagglund Earlier this week, in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 22-1889, 2023 U.S. App. LEXIS 29433 (Fed. Cir....
06 Nov, 2023 Risk of Patent Infringement Unprotected by the Hatch-Waxman Safe Harbor in Cell-Based Therapeutic Product Development By Ryan Hagglund The advent of cell-based therapeutics, such as chimeric antigen receptor T-cells (“CAR-T cells”), as well as their development and...